Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q1 2026 · 10-Q
Revenue$105.40M$105.40M+60.1% vs Q1 2025 Net Income-$11.30M-$11.30MN/M vs Q1 2025 EPS Diluted-$0.09-$0.09N/M vs Q1 2025 Operating Income-$9,089,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
Free Cash Flowderived$2,239,000N/M Margins · derivedOperating margin-8.6%+28.6 pt vs Q1 2025
Net margin-10.7%+27.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end